Semavic® reduces the risk of major adverse cardiovascular events (1) Semavic® Instruction for Medical Use
Semavic® decreases triglycerides and cholesterol concentrations (1) Semavic® Instruction for Medical Use
Semavic® decreases systolic blood pressure (1) Semavic® Instruction for Medical Use
Semavic® decreases blood glucose levels (plasma glucose and glycated haemoglobin (HbA1c)) in adult type 2 diabetes patients (1) Semavic® Instruction for Medical Use
Semavic® suppresses appetite and reduces daily calorie intake by 18–35 % (1) Semavic® Instruction for Medical Use
Semavic® helps lose weight, mainly through fat tissue loss (1) Semavic® Instruction for Medical Use
Semavic® (active ingredient: semaglutide) is indicated as an adjunct therapy to standard treatment of cardiovascular diseases to reduce the risk of major adverse cardiovascular events (MACE) * in patients with type 2 diabetes mellitus and high cardiovascular risk
*MACE, major adverse cardiovascular events: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
Semavic® reduces the risk of major adverse cardiovascular events by 26 % (2) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
*HbA1c is a biochemical metric indicative of the averaged blood glucose level within the previous 3 months. In diabetes (a disease characterised by glucose uptake disorder leading to hyperglycaemia, sustained blood glucose elevation), glucose couples with haemoglobin to produce glycated haemoglobin (HbA1c). The higher the blood glucose level, the more of haemoglobin converts into glycated haemoglobin.
Baseline HbA1c
Baseline HbA1c
End-of-follow-up
HbA1c level
For most adult diabetes patients, the adequate target HbA1c level is below 7.0 % (6) Standards of Specialised Diabetes Care
| Clinical characteristics / risks | Patient category | |||||
|---|---|---|---|---|---|---|
| Young | Middle age / elderly | Elderly / senile | ||||
| Functionally independent | Functionally dependent | |||||
| No senile asthenia and/or dementia | Senile asthenia and/or dementia | End of life | ||||
| No atherosclerotic cardiovascular disease (3) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol and/or risk of severe hypoglycaemia (4) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol | <6,5% | <7,0% | <7,5% | <8,0% | <8,5% | Avoid hypoglycaemia or hypoglycaemic symptoms |
| Atherosclerotic cardiovascular disease and/or risk of severe hypoglycaemia | <7,0% | <7,5% | <8,0% | |||
Semavic® (active ingredient: semaglutide) is not indicated for just weight loss. In clinical trials, weight loss was the secondary endpoint.
Baseline weight
Baseline weight
For most adult diabetes patients, the adequate target HbA1c level is below 7.0 % (1) Semavic® Instruction for Medical Use
The weight loss with semaglutide is mostly due to the loss of fat tissue, which is 3 times greater than the loss of muscle tissue (1) Semavic® Instruction for Medical Use
Semavic® suppresses appetite and reduces daily calorie intake by 18–35 % (1) Semavic® Instruction for Medical Use
Semavic® reduces food cravings, especially for high-fat foods
1.Semavic® Instruction for Medical Use
2.Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844 (SUSTAIN 6).
3.Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017:5(5):355-366.
4.Pratley RE, Aroda VR, Lingvay I, et al, on behalf of the SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286.
5.Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1
6.Standards of Specialised Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. — M.; 2023. doi: https://doi.org/10.14341/DM13042
